Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
4.300
-0.160 (-3.59%)
At close: Mar 31, 2025, 4:00 PM
4.454
+0.154 (3.59%)
After-hours: Mar 31, 2025, 7:29 PM EDT

Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells.

It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency.

Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Jasper Therapeutics, Inc.
Jasper Therapeutics logo
Country United States
Founded 2018
Industry Biotechnology
Sector Healthcare
Employees 64
CEO Ronald Martell

Contact Details

Address:
2200 Bridge Pkwy, Suite 102
Redwood City, California 94065
United States
Phone 650 549 1400
Website jaspertx.com

Stock Details

Ticker Symbol JSPR
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001788028
CUSIP Number 471871103
ISIN Number US4718712023
Employer ID 84-2984849
SIC Code 2836

Key Executives

Name Position
Ronald A. Martell President, Chief Executive Officer and Director
Dr. Judith Anne Shizuru M.D., Ph.D. Co-Founder, Member of Scientific Advisory Board and Director
Herbert C. Cross CPA Chief Financial Officer and Corporate Secretary
Jeetinder Singh Mahal M.B.A. Chief Operating Officer
Dr. Edwin Jonathan Tucker M.D. Chief Medical Officer
David Ku M.D. Vice President of Corporate Development, Portfolio Strategy and Management
Matthew Ford Senior Vice President of Human Resources
Dr. Wendy Pang M.D., Ph.D. Senior Vice President of Research and Translational Medicine
Dr. Luca Di Noto Ph.D. Senior Vice President of Technical Operations
Patricia Carlos Senior Vice President of Regulatory Affairs and Quality

Latest SEC Filings

Date Type Title
Mar 26, 2025 EFFECT Notice of Effectiveness
Mar 26, 2025 424B5 Filing
Mar 19, 2025 8-K Current Report
Mar 19, 2025 S-3 Registration statement under Securities Act of 1933
Feb 28, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 11, 2025 SCHEDULE 13G/A Filing
Jan 8, 2025 8-K Current Report
Dec 12, 2024 144 Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals